← back to search

James W. Dear

The Queen's Medical Research Institute · GB
Area of research
Pharmacology · Emergency Medicine
Research interest
Research interests include Drug-Induced Hepatotoxicity and Protection, Poisoning and overdose treatments, MicroRNA in disease regulation, and Extracellular vesicles in disease.
h-index
54
citations
13,049
works
291
NIH funding
primary concept
Medicine
email

Recent publications

Short communication: Dynamic chemical labelling allows the measurement of the paracetamol toxicity biomarker microRNA-122 in hospital clinical laboratories.
2026cited by 1position: contributordoi
Development of a surface enhanced Raman scattering lateral flow immunoassay with prolonged reproducibility and stability over time.
2026cited by 0position: contributordoi
Roadblocks of Urinary EV Biomarkers: Moving Toward the Clinic.
2025cited by 7position: contributordoi
The emerging role of alternatively activated macrophages to treat acute liver injury.
2025cited by 5position: contributordoi
HiSNAP trial-a multicentre, randomised, open-label, blinded end point, safety and efficacy trial of conventional (300 mg/kg) versus higher doses of acetylcysteine (450 mg/kg and 600 mg/kg) in patients with paracetamol overdose in the UK: study protocol.
2025cited by 3position: contributordoi
Cryopreserved human alternatively activated macrophages promote resolution of acetaminophen-induced liver injury in mouse.
2025cited by 3position: contributordoi
Antidotes in the management of poisoned patients: What have we gained over the last decade?
2025cited by 2position: contributordoi
A point-of-care diagnostic for drug-induced liver injury using surface-enhanced Raman scattering lateral flow immunoassay.
2025cited by 2position: contributordoi
Scottish and Newcastle Antiemetic Protocol (SNAP) 12-hour acetylcysteine regimen for paracetamol overdose reduces anaphylactoid reactions without compromising hepatic protection in all age groups: a secondary analysis.
2025cited by 1position: contributordoi
Adverse drug reactions, particularly liver disorders, drive interruptions in anti-tuberculosis treatment: A retrospective cohort study.
2025cited by 1position: contributordoi
SLAMseq reveals potential transfer of RNA from liver to kidney in the mouse.
2025cited by 1position: contributordoi
Dynamic chemical labelling allows the measurement of the paracetamol toxicity biomarker microRNA-122 in hospital clinical laboratories
2025cited by 0position: contributordoi
Adverse drug reactions, particularly liver disorders, drive prolonged interruptions in anti-tuberculosis treatment: a retrospective cohort study
2025cited by 0position: contributordoi
A new point of care diagnostic for the sensitive and specific diagnosis of drug-induced liver injury using a surface enhanced Raman scattering lateral flow immunoassay (SERS-LFIA)
2025cited by 0position: contributordoi
No action is without its side effects: Adverse drug reactions and missed doses of antituberculosis therapy, a scoping review.
2024cited by 10position: contributordoi
Circulating microRNA detection using electrochemical biosensor for rapid diagnosis of liver disease in dogs
Sensors & Diagnostics 2024cited by 8position: contributordoi
Macrophage Therapy for Acute Liver Injury (MAIL): a study protocol for a phase 1 randomised, open-label, dose-escalation study to evaluate safety, tolerability and activity of allogeneic alternatively activated macrophages in patients with paracetamol-induced acute liver injury in the UK.
2024cited by 6position: contributordoi
Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP biomarker substudy).
2024cited by 2position: contributordoi
Study protocol: HiSNAP trial – a multi-centre, randomised, open label, blinded end-point, safety and efficacy trial of conventional (300mg/kg) versus higher doses of acetylcysteine (450mg/kg and 600mg/kg) in patients with paracetamol overdose in the United Kingdom
2024cited by 2position: contributordoi
Candidate circulating microRNA biomarkers in dogs with chronic pancreatitis.
2024cited by 1position: contributordoi
Macrophage Therapy for Acute Liver Injury (MAIL): a Phase 1 Randomised, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Activity of Allogeneic Alternatively Activated Macrophages in Patients with Paracetamol-induced Acute Liver Injury
2024cited by 1position: contributordoi
SLAMseq reveals transfer of RNA from liver to kidney in the mouse
2024cited by 0position: contributordoi
Cryopreserved human alternatively activated macrophages promote resolution of acetaminophen-induced liver injury in mouse
2024cited by 0position: contributordoi
Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review.
2023cited by 84position: contributordoi
Choroidal and retinal thinning in chronic kidney disease independently associate with eGFR decline and are modifiable with treatment
Nature Communications 2023cited by 31position: middledoi
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE).
2023cited by 30position: contributordoi
Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans.
2023cited by 26position: contributordoi
Choroidal and retinal thinning in chronic kidney disease independently associate with eGFR decline and are modifiable with treatment.
2023cited by 22position: contributordoi
No action is without its side effects: Adverse drug reactions and missed doses of antituberculosis therapy, a scoping review
British Journal of Clinical Pharmacology 2023cited by 12position: middledoi
Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973-2023 with particular focus on contributions published from Edinburgh and Denver.
2023cited by 9position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 54 papers (2019–2026)Christopher J Weir · University College London9 papers (2019–2026)Matthew A. Bailey · University of Edinburgh8 papers (2015–2025)David J. Webb · Western General Hospital7 papers (2019–2024)Robert W. Hunter · Edinburgh Royal Infirmary6 papers (2021–2025) · 5 papers (2021–2025)Eleanor G. Dixon · HM Prison Service4 papers (2023–2025)John Norrie · London School of Hygiene & Tropical Medicine4 papers (2021–2023)Karen Faulds · University of Strathclyde4 papers (2022–2026)Christopher Humphries · Cardiff University4 papers (2024–2025)Stuart J. Forbes · Queen's Medical Centre4 papers (2024–2025)David M. Wood · Guy's and St Thomas' NHS Foundation Trust4 papers (2014–2019)Paul I. Dargan · King's College London4 papers (2014–2019)David J. Webb · University of Leicester4 papers (2013–2019)Guruprasad P. Aithal · NIHR Nottingham Hearing Biomedical Research Unit3 papers (2021–2024)D. Nicholas Bateman · University of Edinburgh3 papers (2013–2015)Neeraj Dhaun · Jisc3 papers (2022–2025)D. N. Bateman · University Hospitals of Leicester NHS Trust3 papers (2019–2023)Maria Elena Candela · The University of Edinburgh3 papers (2024–2025)Simon H. L. Thomas · St Thomas' Hospital3 papers (2014–2019)